Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,069 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed No phase listed Observational

SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial

NCT00002900
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
management of therapy complications
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
105
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 20, 2026, 6:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

NCT04985032
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
RPCR, Inc.
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Molecular Breast Imaging in Women With Atypia and LCIS

NCT00620087
View directory record Official record
Conditions
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
Interventions
Molecular Breast Imaging, Screening Mammography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 20, 2026, 6:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer

NCT00086749
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
20 Years to 45 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Phase 1 Interventional

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02576548
View directory record Official record
Conditions
HER2 Expressing Breast or Gastric/Stomach Cancers
Interventions
MEDI4276
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Stanford, California • Sarasota, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Phase 2 Interventional

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

NCT00165204
View directory record Official record
Conditions
Menopause, Postmenopausal Bone Loss, Breast Cancer
Interventions
Tibolone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Oct 20, 2026, 6:01 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
View directory record Official record
Conditions
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Atezolizumab, Cobimetinib, Eribulin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Phase 1 Interventional Results available

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

NCT02898207
View directory record Official record
Conditions
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
Interventions
Olaparib, Onalespib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients

NCT03289364
View directory record Official record
Conditions
Breast Cancer
Interventions
Penguin Cold Caps
Device
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Phase 3 Interventional

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

NCT00003884
View directory record Official record
Conditions
Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
zoledronic acid, quality-of-life assessment
Drug · Procedure
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
55
States / cities
Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 20, 2026, 6:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microvascular Function in Patients Undergoing 5-Fluorouracil Chemotherapy

NCT04042298
View directory record Official record
Conditions
Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Chemotherapy Effect, 5-Fluorouracil Toxicity
Interventions
Arterial blood pressure, Skin microcirculatory blood flow, Brachial artery blood flow, Venous blood draw
Other
Lead sponsor
Kansas State University
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 20, 2026, 6:01 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

NCT05191004
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions
NUV-422, Fulvestrant
Drug
Lead sponsor
Nuvation Bio Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 20, 2026, 6:01 AM EDT
Recruiting Early Phase 1 Interventional

Breast Cancer PSMA PET

NCT06586047
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
PET imaging
Diagnostic Test
Lead sponsor
Ahmad Shariftabrizi
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Completed Not applicable Interventional

Behavioral Weight Loss Program for Cancer Survivors in Maryland

NCT04534309
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer, Gallbladder Cancer, Rectal Cancer, Kidney Cancer, Bladder Cancer
Interventions
Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 6:01 AM EDT
Completed No phase listed Observational

QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser

NCT01803516
View directory record Official record
Conditions
Breast Cancer, Radiation-Induced Telangiectasias
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 20, 2026, 6:01 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Aspen™ Ultrasound System and Aspen Rehabilitation Technique in the Treatment of Capsular Contracture

NCT02840084
View directory record Official record
Conditions
Capsular Contracture of Breast, Grade III
Interventions
Aspen(TM) Ultrasound System
Device
Lead sponsor
Nina Naidu
Individual
Eligibility
22 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 20, 2026, 6:01 AM EDT
Recruiting Phase 2 Interventional

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

NCT06105684
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine Pill
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional

Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer

NCT00159458
View directory record Official record
Conditions
Recurrent Breast Cancer, Metastastic Breast Cancer
Interventions
Gemcitabine and oxaliplatin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 20, 2026, 6:01 AM EDT
Completed No phase listed Observational

Comparison of PEM Uptake Value (PUV) and Standardized Uptake Value (SUV) in Patients With Malignancies of the Breast

NCT01031238
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 20, 2026, 6:01 AM EDT
Enrolling by invitation Not applicable Interventional

Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

NCT07381985
View directory record Official record
Conditions
Hereditary Cancer Syndromes, BRCA1 Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome
Interventions
Longitudinal Cancer Genetics Follow-Up Program
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Drug · Procedure
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 6:01 AM EDT
Recruiting Not applicable Interventional

Survivors Uniting for Remote Guided Exercise

NCT07290309
View directory record Official record
Conditions
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions
Virtually Supervised Exercise Sessions, Asynchronous Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 6:01 AM EDT